Exicure shares are trading higher after the company announced results from its completed Phase 2 trial evaluating burixafor combination with propranolol and granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation achieved its primary endpoint.

Exicure Reports Positive Phase 2 Results for Burixafor in Multiple Myeloma Stem Cell Mobilization

Exicure Inc. announced positive Phase 2 trial results for burixafor in multiple myeloma stem cell mobilization, achieving the primary endpoint in 90% of participants. The study showed favorable safety and rapid mobilization kinetics, with peak CD34+ cell levels within one hour of administration. Results were presented at the 2025 ASH Annual Meeting.

Exicure Inc. Announces Early Redemption of $3.1 Million Convertible Bonds to Simplify Capital Structure

Exicure Inc. announced the early redemption of $3.1 million in convertible bonds, originally due in 2028, to streamline its capital structure. The bonds were redeemed internally, funded through cash transfers, and are not expected to impact the company's financial statements materially. This move supports Exicure's biotechnology operations.

Exicure Inc. Held Annual Shareholder Meeting

Exicure Inc. held its 2025 Annual Meeting of Stockholders on November 6, 2025, where stockholders elected two new board members and ratified CBIZ CPAs P.C. as the independent accounting firm for the fiscal year ending December 31, 2025. All proposals presented were approved.

Exicure | 10-Q: FY2025 Q3 Revenue: USD 0